Abbas Al Temimi

Highly skilled R&D Scientist with professional international experience in medicinal organic and peptide chemistry. Demonstrated track record of success, creativity, and research productivity with multiple peer-reviewed publications and scientific awards. Possesses broad scientific background in design, synthesis, purification, and characterization of small organic/medicinal molecules, amino acids building blocks, and peptides modalities. Profound theoretical knowledge about ADCs and oligonucleotides, along with expertise in executing organic chemical synthesis projects. Strong documentation and reporting skills for drug products, as well as project management abilities. Excellent communication skills and a self-motivated team player with a good sense of humor. Goal-oriented work ethic and can-do attitude, always ready to assist where needed. Passionate about utilizing science to enhance human health and contribute to company's success.

• Tres Cantos Open Lab Foundation Recipient, GSK, 10/01/21, Tres Cantos - Madrid, Spain
• IMM Award for the best PhD thesis in Chemistry, Radboud University, the Netherlands, 04/22/21
• PhD degree with honors Distinction Cum Laude, Radboud University, the Netherlands, 06/19/20
• Best Poster Award, IMM Symposium at Radboud University, 10/30/17

• Scientist Medicinal Chemist, GSK, Tres Cantos - Madrid, Spain, 01/01/22, Present, Currently, my work focuses on the medicinal chemistry synthesis of high quality antimalarial hits at a leading biopharmaceutical company GSK in collaboration with the scientists at UCSD and Harvard in the US.
• R&D PhD Researcher - Highest Distinction Cum Laude, Radboud University, the Netherlands, 06/01/15, 09/30/20, Thesis title: Investigation of Methylation Catalysis of Unnatural Histone Peptides by Histone Lysine Methyltransferases. Chemical epigenetics in cancer disease.
• Synthetic Organic Chemist (Trainee), Symeres B.V., the Netherlands, 10/01/18, 12/31/18, Project based on the synthesis of geometrically constrained lysine-based building blocks that were incorporated into histone peptides, and evaluated for methylation catalysis and binding.
• Research Scientist Organic Chemist, Okklo Life Sciences B.V, Oss, the Netherlands, 06/01/14, 05/31/15, Collaboration between the synthetic organic chemistry group at Radboud University and Okklo Life Sciences BV. Project based on the design and synthesis of a novel cyclodextrin-linker peptide aiming for drug delivery.

- Al Temimi et al. Communications Chemistry- Nature, 2019, 2, 112, https://www.nature.com/articles/s42004-019-0210-8,

- Al Temimi et al. Org. Lett., 2017, 19, 2, 400-403, https://pubs.acs.org/doi/abs/10.1021/acs.orglett.6b03608

- Al Temimi et al. Bioconjugate. Chem., 2017, 28, 8, 2160-2166, https://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.7b00319

- Al Temimi et al. Chem. Commun., 2020, 56, 3039-3042, https://pubs.rsc.org/en/content/articlehtml/2020/cc/c9cc09098c

- Al Temimi et al. Sci. Rep., 2020, 10, 21574, https://www.nature.com/articles/s41598-020-78331-0

• Prof. dr. Floris P. J. T. Rutjes, floris.rutjes@ru.nl
• Dr. Felix Calderon, Director of Medicinal Chemistry at ViiV Healthcare, felix.x.calderon@viivhealthcare.com
• Dr. Jose Ignacio Martin Hernando, jose.i.martin@gsk.com
• Prof. dr. Jasmin Mecinović, mecinovic@sdu.dk

• Travelling
• Fitness training and sport
• Walking in nature
• Swimming
• Cinema
• Socializing with friends